By Matthew Stenger Posted: 4/14/2021 12:36:00 PM Last Updated: 4/16/2021 2:59:18 PM In the Chinese phase III RATIONALE 307 trial reported in JAMA Oncology, Wang et al found that tislelizumab plus chemotherapy significantly prolonged progression-free survival vs chemotherapy…
On April 18, the U.S. Food and Drug Administration (FDA) approved the tyrosine kinase inhibitor alectinib (Alecensa) for adjuvant treatment after tumor resection in patients…
Researchers have identified a novel screening strategy to improve early detection of pancreatic cancer in high-risk patients.
Natalie S. Callander, MD, of the University of Wisconsin Carbone Cancer Center, discusses advances in the treatment of patients with multiple myeloma, including her commentary…
Investigators have assessed the rate of survival in patients with intellectual and developmental disabilities diagnosed with breast cancer, colorectal cancer, or lung cancer.
Natalie S. Callander, MD, of the University of Wisconsin Carbone Cancer Center, discusses advances in the treatment of patients with multiple myeloma, including her commentary…
In the phase II PHERGain trial, researchers found that a positron-emission tomography (PET)-based, pathologic complete response (pCR)-adapted treatment strategy produced “excellent” 3-year invasive di…
A recent study explored the mechanisms behind conventional immunotherapy resistance as well as the efficacy of adoptive therapy in patients with metastatic uveal melanoma.
Investigators have uncovered persistent inequities in breast cancer that may systematically leave many patients behind in spite of recent improvements in research, treatment, and survival,…
Success stories in research, advocacy, and education from low- and middle-income countries deserve international recognition to motivate the next generation of researchers and practitioners and…
Concurrent cisplatin, gemcitabine, and intensity-modulated radiation therapy (IMRT) produced a high rate of complete pathologic response in patients with locally advanced vulvar squamous cell carcinom…
